自引率: 3.3%
被引量: 45813
通过率: 暂无数据
审稿周期: 1.83
版面费用: 暂无数据
国人发稿量: 272
投稿须知/期刊简介:
The succes of Annals of Oncology is built upon the following pillars: The support of a strong and growing society (ESMO) ensures a standard of excellence. Annals of Oncology publishes papers related to medical oncology surgery radiotherapy paediatric oncology basic research and the comprehensive management of patients with malignant diseases. Each issue includes educational clinical cases original articles reviews controversies news and letters. Annals of Oncology publishes highly selected articles and editorials from worldwide experts. On average articles are reviewed within five weeks and published within three months from acceptance. The rejection rate of manuscripts offered to Annals of Oncology is above seventy five percent.
期刊描述简介:
From Biology to Clinical practice : a modern approach of oncology. While giving space to review articles and paying more attention to biological aspects, the Bulletin du Cancer maintains a highly scientific clinical and therapeutic approach. The Bulletin du Cancer has now become one of the best scientific publications in the French language in the realm of cancerology. It is listed in the leading international databases. The Bulletin du Cancer is the journal of the Société Française du Cancer. The online version of Bulletin du Cancer is now available, offering seven years of archives that can be accessed by pay per view or by subscription.
-
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
被引量:- 发表:1970
-
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.
被引量:1 发表:1970
-
Reply to the manuscript 'A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse' by J.-Y. Blay et al.
被引量:- 发表:1970
-
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
被引量:- 发表:1970
-
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
被引量:- 发表:1970